Document is current
Any future updates will be listed below
-
Authors
Zhao, Yang https://orcid.org/0000-0002-6596-499X
Ogishi, Masato https://orcid.org/0000-0003-2421-7389
Pal, Aastha
Su, Leon L. https://orcid.org/0000-0001-7654-9997
Tao, Pingdong
Jiang, Hua
Rodriguez, Grayson E. https://orcid.org/0009-0002-7386-2050
Chen, Xiaojing
Sun, Qinli
Rysavy, Lea Wenting
Limsuwannarot, Sam https://orcid.org/0000-0001-8714-7221
Waghray, Deepa
Kalbasi, Anusha https://orcid.org/0000-0001-8692-1457
Garcia, K. Christopher https://orcid.org/0000-0001-9273-0278
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 10 July 2025
First Online: 13 August 2025
Change Date: 15 September 2025
Change Type: Update
Change Details: This paper was originally published under Creative Commons Attribution 4.0 International license, CC-BY-NC-ND, © The Author(s). It is now available under a Creative Commons Attribution 4.0 International license, CC-BY, © The Author(s). The error has been corrected in the online version of the article.
Competing interests
: K.C.G. is the founder of Synthekine and co-founder of Dispatch Therapeutics, which are developing cytokine receptor-based therapeutics. The chimeric receptors in this study are described in a pending patent application (PCT/US2016/050511). A.K. serves on the advisory board for and holds stock in Dispatch Therapeutics and Certis Oncology and consults for Sastra Cell Therapy. The other authors declare no competing interests.
